Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer

被引：0
|
作者：
Peter A. Fasching
Paul Gass
Lothar Häberle
Bernhard Volz
Alexander Hein
Carolin C. Hack
Michael P. Lux
Sebastian M. Jud
Arndt Hartmann
Matthias W. Beckmann
Dennis J. Slamon
Ramona Erber
机构：
[1] Friedrich Alexander University of Erlangen-Nuremberg,Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen
[2] University of California at Los Angeles,EMN, Erlangen University Hospital
[3] Friedrich Alexander University of Erlangen-Nuremberg,Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine
[4] Friedrich Alexander University of Erlangen-Nuremberg,Biostatistics Unit, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen
来源：
Breast Cancer Research and Treatment | 2019年 / 175卷
关键词：
Breast cancer; Ki-67; Proliferation; Molecular marker; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：617 / 625
页数：8
相关论文
共 50 条
  • [41] Prognostic Implications of Magee Equation 3 and Residual Cancer Burden in Patients Receiving Neoadjuvant Chemotherapy for Hormone Receptor-Positive HER2-Negative Breast Cancer
    Vazquez, Thais Perez
    Goncalves, Rodrigo
    da Cunha, Juliana Pierobon Gomes
    Rivas, Fernando Wladimir Silva
    Aguiar, Fernando Nalesso
    Baracat, Edmund Chada
    Filassi, Jose Roberto
    MODERN PATHOLOGY, 2025, 38 (06)
  • [42] The Difference in Prognostic Outcomes Between De Novo Stage IV and Recurrent Metastatic Patients with Hormone Receptor-positive, HER2-negative Breast Cancer
    Yamamura, Jun
    Kamigaki, Shunji
    Fujita, Junya
    Osato, Hiroki
    Komoike, Yoshifumi
    IN VIVO, 2018, 32 (02): : 353 - 358
  • [43] Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
    Ogiya, Akiko
    Yamazaki, Kieko
    Horii, Rie
    Shien, Tadahiko
    Horimoto, Yoshiya
    Masuda, Norikazu
    Inao, Touko
    Hosoda, Mitsuchika
    Ishida, Naoko
    Osako, Tomofumi
    Takahashi, Masato
    Endo, Yumi
    Miyoshi, Yuichiro
    Yasojima, Hiroyuki
    Tomioka, Nobumoto
    Yamashita, Hiroko
    BREAST CANCER, 2017, 24 (03) : 473 - 482
  • [44] Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
    Akiko Ogiya
    Kieko Yamazaki
    Rie Horii
    Tadahiko Shien
    Yoshiya Horimoto
    Norikazu Masuda
    Touko Inao
    Mitsuchika Hosoda
    Naoko Ishida
    Tomofumi Osako
    Masato Takahashi
    Yumi Endo
    Yuichiro Miyoshi
    Hiroyuki Yasojima
    Nobumoto Tomioka
    Hiroko Yamashita
    Breast Cancer, 2017, 24 : 473 - 482
  • [45] Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
    Fernandez-Martinez, Aranzazu
    Pascual, Tomas
    Perrone, Giuseppe
    Morales, Serafin
    de la Haba, Juan
    Gonzalez-Rivera, Milagros
    Galvan, Patricia
    Zalfa, Francesca
    Amato, Michela
    Gonzalez, Lucia
    Prats, Miquel
    Rojo, Federico
    Manso, Luis
    Pare, Laia
    Alonso, Immaculada
    Albanell, Joan
    Vivancos, Ana
    Gonzalez, Antonio
    Matito, Judit
    Gonzalez, Sonia
    Fernandez, Pedro
    Adamo, Barbara
    Munoz, Montserrat
    Viladot, Margarita
    Font, Carme
    Aya, Francisco
    Vidal, Maria
    Caballero, Rosalia
    Carrasco, Eva
    Altomare, Vittorio
    Tonini, Giuseppe
    Prat, Aleix
    Martin, Miguel
    ONCOTARGET, 2017, 8 (13) : 21930 - 21937
  • [46] Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients
    Wiesner, Folkward G.
    Magener, Achim
    Fasching, Peter A.
    Wesse, Julia
    Bani, Mayada R.
    Rauh, Claudia
    Jud, Sebastian
    Schrauder, Michael
    Loehberg, Christian R.
    Beckmann, Matthias W.
    Hartmann, Arndt
    Lux, Michael P.
    BREAST, 2009, 18 (02) : 135 - 141
  • [47] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
    Wekking, Demi
    Leoni, Vera Piera
    Lambertini, Matteo
    Dessi, Mariele
    Pretta, Andrea
    Cadoni, Andrea
    Atzori, Luigi
    Scartozzi, Mario
    Solinas, Cinzia
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
  • [48] The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
    Zhang, Ailin
    Wang, Xiaojing
    Fan, Chuifeng
    Mao, Xiaoyun
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [49] Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
    Schwartzberg, Lee S.
    Kiedrowski, Lesli A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [50] Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Joo, Eun Hye
    Kim, Sangmin
    Park, Donghyun
    Lee, Taeseob
    Park, Woong-Yang
    Han, Kyung Yeon
    Lee, Jeong Eon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
12345